Iranian Coronavirus Vaccine Finds Swiss Customers

  February 01, 2021   News ID 1763
Iranian Coronavirus Vaccine Finds Swiss Customers
Switzerland is negotiating with non-Western countries, including Iran, to import COVID-19 vaccine as five Iranian companies have registered coronavirus vaccine development projects at the World Health Organization.

Tehran, SAEDNEWS, Feb. 1: Due to the shortage of coronavirus vaccine in Switzerland, the Swiss health ministry is negotiating with non-Western producers, such as Iran and Egypt, as Bern is likely to buy the vaccine from these countries, according to a Swiss daily.

With regard to the challenges of the Pfizer and Moderna vaccines in Europe, the continent and Switzerland are facing serious shortage of the vaccine.

“We have good relations with the Iranian health sector. Health institutions in Iran are well organized and fully equipped for clinical trials and data sets,” IRIB reported Vice-Director General of the Federal Office of Public Health of Switzerland Nora Kronig as saying.

“Five Iranian institutions are on the list of the World Health Organization’s nominees for the vaccine,” Kronig added.

In relevant remarks on Sunday, Iranian Health Minister Saeed Namaki said that the country will turn into a center for production of coronavirus vaccine in spring given the successful results of the human trial of its home-made vaccines.

“Our country will become one of the poles to produce coronavirus vaccine next spring,” Namaki said.

He stressed the successful results of the human trial of Iran-made coronavirus vaccines, and said, “We are vigorously pursuing the indigenous vaccine, and we import both the COVAX vaccines and vaccines from the safest sources.”

Namaki also underlined the Iranian knowledge-based companies’ capabilities to produce different medical equipment, saying that in the first two months of the coronavirus outbreak in Iran, 300 oxygen-generator systems and 5,000 oxygen capsules were manufactured in the country.

He added that the health ministry has increased 2,500 ICU beds at hospitals across the country after the coronavirus outbreak.

Earlier on Sunday, Spokesman of Iran's Food and Drug Organization (IFDA) Kianoush Jahanpour said that the coronavirus vaccine developed by the Headquarters for Executing Imam Khomeini’s Order (HEIKO) affiliated to Barekat Foundation in Iran enjoys the unique capability to deactivate the COVID-19 virus mutations in Britain and South Africa.

“The coronavirus vaccine produced by Barekat Foundation is highly effective in fighting coronavirus,” Jahanpour said.

“The Iranian coronavirus vaccine has surprised the world because it is being manufactured in the best conditions and with very high quality and is in the final stages, and we hope that a mass production license will be issued in the middle of the third phase (of human trial) and it will be available in late spring next year,” he added.

“One of the advantages of the Iranian coronavirus vaccine compared to other vaccines in the world is its unique ability to affect the British virus mutation and it has been able to overcome the disease based on clinical tests,” Jahanpour said (Source: Fars News).